Kestra Medical Technologies (KMTS) insider plans 13,015-share NASDAQ sale

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. (KMTS) reports a planned sale of 13,015 shares of common stock through Merrill Lynch on or about 07/31/2026, to be traded on NASDAQ. These shares relate to performance share unit awards that vested on 07/17/2026 and were granted under the issuer’s equity compensation plan.

Alfred J. Ford previously sold 5,936 shares of common stock for $135,120.73 on 07/30/2026 and 8,681 shares for $196,284.58 on 07/31/2026.

Key Figures

Shares planned for sale: 13,015 shares Aggregate market value of planned sale: $311,118.83 Shares from PSU vesting: 13,015 shares +4 more

7 metrics

Shares planned for sale 13,015 shares Common stock to be sold through Merrill Lynch on or about 07/31/2026

Aggregate market value of planned sale $311,118.83 Value of 13,015 common shares proposed for sale

Shares from PSU vesting 13,015 shares Shares from vesting of performance share unit awards on 07/17/2026

Shares sold 07/30/2026 5,936 shares Common stock sold by Alfred J. Ford for $135,120.73

Proceeds 07/30/2026 sale $135,120.73 Sale of 5,936 common shares by Alfred J. Ford

Shares sold 07/31/2026 8,681 shares Common stock sold by Alfred J. Ford for $196,284.58

Proceeds 07/31/2026 sale $196,284.58 Sale of 8,681 common shares by Alfred J. Ford

Key Terms

performance share unit awards, equity compensation plan, vesting

3 terms

performance share unit awards financial

"Common Stock | 07/17/2026 | Vesting of performance share unit awards"

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

vesting financial

"07/17/2026 | Vesting of performance share unit awards"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 04:45 PM Accepted by SEC EDGAR 08/03/2026 - 04:44 PM Learn about SEC filing dates

FAQ

What stock sale is disclosed for Kestra Medical Technologies (KMTS)?

Kestra Medical Technologies discloses a planned sale of 13,015 shares of common stock through Merrill Lynch on or about 07/31/2026 on NASDAQ. The shares stem from vested performance share unit awards under the company’s equity compensation plan.

How many KMTS shares did Alfred J. Ford sell recently?

Alfred J. Ford sold 5,936 KMTS shares for $135,120.73 on 07/30/2026 and 8,681 shares for $196,284.58 on 07/31/2026. These transactions are reported as sales of common stock.

What is the aggregate market value of KMTS shares planned for sale?

The planned sale covers 13,015 KMTS common shares with an aggregate market value of $311,118.83. These shares are expected to be sold on NASDAQ, with Merrill Lynch identified as the broker handling the transaction.

What is the source of the KMTS shares being sold under this notice?

The 13,015 shares planned for sale arise from the vesting of performance share unit awards on 07/17/2026. These awards were granted as part of the issuer equity compensation plan of Kestra Medical Technologies, Ltd.

On what date are the KMTS shares expected to be sold on NASDAQ?

The KMTS common shares are expected to be sold on or about 07/31/2026 on NASDAQ. Merrill Lynch is listed as the broker, and the aggregate market value of the 13,015 planned shares is $311,118.83.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	13015	311118.83	58602497	07/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/17/2026	Vesting of performance share unit awards	KESTRA MEDICAL TECHNOLOGIES, LTD.			13015	07/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Alfred J Ford 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	07/30/2026	5936	135120.73
Alfred J Ford 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	07/31/2026	8681	196284.58

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)